141 related articles for article (PubMed ID: 25028935)
1. Diesterified derivatives of 5-iodo-2'-deoxyuridine as cerebral tumor tracers.
Rösler TW; Matusch A; Librizzi D; Arias-Carrión O; Freundlieb N; Hoeffken H; Oertel WH; Depboylu C; Höglinger GU
PLoS One; 2014; 9(7):e102397. PubMed ID: 25028935
[TBL] [Abstract][Full Text] [Related]
2. 5-[123I/125I]iodo-2'-deoxyuridine in metastatic lung cancer: radiopharmaceutical formulation affects targeting.
Semnani ES; Wang K; Adelstein SJ; Kassis AI
J Nucl Med; 2005 May; 46(5):800-6. PubMed ID: 15872354
[TBL] [Abstract][Full Text] [Related]
3. Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver.
Macapinlac HA; Kemeny N; Daghighian F; Finn R; Zhang J; Humm J; Squire O; Larson SM
J Nucl Med; 1996 Apr; 37(4 Suppl):25S-29S. PubMed ID: 8676200
[TBL] [Abstract][Full Text] [Related]
4. 5-[125]iodo-2'-deoxyuridine in the radiotherapy of solid CNS tumors in rats.
Kassis AI; Adelstein SJ
Acta Oncol; 1996; 35(7):935-9. PubMed ID: 9004774
[TBL] [Abstract][Full Text] [Related]
5. Tumor uptake and mitotic activity pattern of 5-[125I]iodo-2'- deoxyuridine after intravesical infusion in patients with bladder cancer.
Mariani G; Collecchi P; Baldassarri S; Di Luca L; Buralli S; Fontanini G; Baranowska-Kortylewicz J; Adelstein SJ; Kassis AI
J Nucl Med; 1996 Apr; 37(4 Suppl):16S-19S. PubMed ID: 8676197
[TBL] [Abstract][Full Text] [Related]
6. Effects of DNA-targeted ionizing radiation produced by 5-[125I]iodo-2'-deoxyuridine on global gene expression in primary human cells.
Sokolov MV; Neumann RD; Panyutin IG
BMC Genomics; 2007 Jun; 8():192. PubMed ID: 17594496
[TBL] [Abstract][Full Text] [Related]
7. Radiolabeled nucleoside analogs in cancer diagnosis and therapy.
Kassis AI; Adelstein SJ; Mariani G
Q J Nucl Med; 1996 Sep; 40(3):301-19. PubMed ID: 8961807
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral administration of 5-[123I]iodo-2'-deoxyuridine in a patient with a brain tumor.
Kassis AI; Tumeh SS; Wen PY; Baranowska-Kortylewicz J; Van den Abbeele AD; Zimmerman RE; Carvalho PA; Garada BM; DeSisto WC; Bailey NO; Castronovo FP; Mariani G; Black PM; Adelstein SJ
J Nucl Med; 1996 Apr; 37(4 Suppl):19S-22S. PubMed ID: 8676198
[TBL] [Abstract][Full Text] [Related]
9. Tumor targeting by intra-arterial infusion of 5-[123I]iodo-2'-deoxyuridine in patients with liver metastases from colorectal cancer.
Mariani G; Di Sacco S; Volterrani D; Di Luca L; Buralli S; Di Stefano R; Baranowska-Kortylewicz J; Bonora D; Matteucci F; Ricci S; Bellina CR; Falcone A; Salvadori PA; Mosca F; Adelstein SJ; Kassis AI
J Nucl Med; 1996 Apr; 37(4 Suppl):22S-25S. PubMed ID: 8676199
[TBL] [Abstract][Full Text] [Related]
10. Iodo-2'-deoxyuridine (IUdR) and 125IUdR loaded biodegradable microspheres for controlled delivery to the brain.
Reza MS; Whateley TL
J Microencapsul; 1998; 15(6):789-801. PubMed ID: 9818956
[TBL] [Abstract][Full Text] [Related]
11. Targeting tumors with iodine-123 labeled deoxyuridine: distribution and DNA binding.
Thakur ML; Li J; Kim SM; Zhang JJ; Andrews D
Cancer Detect Prev; 1999; 23(1):72-7. PubMed ID: 9892993
[TBL] [Abstract][Full Text] [Related]
12. Biochemical modulation by 5-fluorouracil and 1-folinic acid of tumor uptake of intra-arterial 5-[123I]iodo-2'deoxyuridine in patients with liver metastases from colorectal cancer.
Mariani G; Di Sacco S; Bonini R; Di Luca L; Buralli S; Bonora D; Ricci S; Baranowska-Kortylewicz J; Adelstein SJ; Falcone A; Kassis AI
Acta Oncol; 1996; 35(7):941-5. PubMed ID: 9004775
[TBL] [Abstract][Full Text] [Related]
13. Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model.
Mairs RJ; Wideman CL; Angerson WJ; Whateley TL; Reza MS; Reeves JR; Robertson LM; Neshasteh-Riz A; Rampling R; Owens J; Allan D; Graham DI
Br J Cancer; 2000 Jan; 82(1):74-80. PubMed ID: 10638969
[TBL] [Abstract][Full Text] [Related]
14. Tumor-targeting potential of radioiodinated iododeoxyuridine in bladder cancer.
Van den Abbeele AD; Tutrone RF; Berman RM; Baranowska-Kortylewicz J; Barclay PD; Richie JP; Adelstein SJ; Kassis AI
J Nucl Med; 1996 Feb; 37(2):315-20. PubMed ID: 8667069
[TBL] [Abstract][Full Text] [Related]
15. Instantaneous preparation of radiolabeled 5-iodo-2'-deoxyuridine.
Foulon CF; Zhang YZ; Adelstein SJ; Kassis AI
Appl Radiat Isot; 1995 Oct; 46(10):1039-46. PubMed ID: 7496371
[TBL] [Abstract][Full Text] [Related]
16. Rationale of 5-(125)I-iodo-4'-thio-2'-deoxyuridine as a potential iodinated proliferation marker.
Toyohara J; Hayashi A; Sato M; Tanaka H; Haraguchi K; Yoshimura Y; Yonekura Y; Fujibayashi Y
J Nucl Med; 2002 Sep; 43(9):1218-26. PubMed ID: 12215562
[TBL] [Abstract][Full Text] [Related]
17. Preclinical animal studies with radioiododeoxyuridine.
Kassis AI; Adelstein SJ
J Nucl Med; 1996 Apr; 37(4 Suppl):10S-12S. PubMed ID: 8676195
[TBL] [Abstract][Full Text] [Related]
18. An in vivo comparison of oral 5-iodo-2'-deoxyuridine and 5-iodo-2-pyrimidinone-2'-deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT-116.
Kinsella TJ; Kunugi KA; Vielhuber KA; McCulloch W; Liu SH; Cheng YC
Cancer Res; 1994 May; 54(10):2695-700. PubMed ID: 8168099
[TBL] [Abstract][Full Text] [Related]
19. Radiosynthesis, in vitro cellular uptake and in vivo biodistribution of 3'-O-(3-benzenesulfonylfuroxan-4-yl)-5-[125I]iodo-2'-deoxyuridine, a nucleoside-based nitric oxide donor.
Moharram S; Zhou A; Kumar P; Knaus EE; Wiebe LI
Nucl Med Biol; 2005 Aug; 32(6):641-5. PubMed ID: 16026711
[TBL] [Abstract][Full Text] [Related]
20. The preparation of clinical grade 5-[123I]iodo-2'-deoxyuridine and 5-[125I]iodo-2'-deoxyuridine with high in vitro stability and the potential for early proliferation scintigraphy.
Schaffland AO; Delaloye AB; Kosinski M; Dupertuis YM; Buchegger F
Nucl Med Commun; 2004 May; 25(5):461-8. PubMed ID: 15100504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
